Comparative Metabolic Profiling and Biological Evaluation of Essential Oils from Conocarpus Species: Antidiabetic, Antioxidant, and Antimicrobial Potential

锥果木属植物精油的代谢谱比较分析和生物学评价:抗糖尿病、抗氧化和抗菌潜力

阅读:1

Abstract

Essential oils (EOs) are a diverse source of bioactive compounds with remarkable therapeutic potential. Despite their significance, Conocarpus EOs have been largely underexplored. This study provides a novel comparison of the metabolic profiles and biological activities of EOs from C. lancifolius, C. erectus green, and C. erectus silver leaves cultivated in the United Arab Emirates (UAE), offering unique insights into their distinct bioactive properties and potential therapeutic applications. EOs were extracted via hydro-distillation, analyzed using gas chromatography-mass spectrometry (GC-MS), and subjected to chemometric analysis. Their antioxidant (2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric reducing ability of plasma (FRAP) assays), antidiabetic (α-amylase and α-glucosidase inhibition), acetylcholinesterase (AChE) inhibition and antimicrobial activities were assessed. A total of 92 metabolites were identified, with heptacosane and nonacosane as key species discriminants. C. lancifolius EO showed the strongest α-amylase (IC(50) 8.75 ± 0.54 µg/mL) and α-glucosidase (IC(50) 22.31 ± 0.92 µg/mL) inhibitory activities, while C. erectus silver demonstrated superior antioxidant capacity (IC(50) 349.78 ± 8.26 µg/mL, DPPH assay). C. lancifolius EO exhibited the best antimicrobial activity, particularly against Staphylococcus aureus (MIC 625 µg/mL). C. erectus silver EO inhibited E. coli and C. albicans (MIC 625 µg/mL). In contrast, C. erectus EOs showed no activity against Aspergillus niger. These findings highlight the potential of Conocarpus EOs as antioxidants and for managing diabetes that may be utilized either in nutraceuticals, dietary supplements or even in pharmaceutical formulations. Moreover, owing to significant antimicrobial activities, the EOs may be added to medical disinfectants and several pharmaceutical products. However, further, in vivo validation and pharmaceutical exploration is still needed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。